Neoleukin Therapeutics Return on Equity

Neoleukin Therapeutics (NLTX) currently reports a ROE of -41.48%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Neoleukin Therapeutics's ROE history and peer comparisons.

Neoleukin Therapeutics's ROE of -41.48% is lower than the Healthcare sector average of 29.33%. That is roughly 241.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Neoleukin Therapeutics's current -41.48% should be judged against Healthcare norms (sector average: 29.33%) and against NLTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -41.48%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Neoleukin Therapeutics, and consider following NLTX for alerts when major investors trade the stock.

Neoleukin Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -41.48% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NLTX with unrelated industries.